Exome Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Exome Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-117,783	Closed	-$1.81M	–	86
2025 Q3	$1.81M	Sell	117,783 -190,515	-62%	-$2.49M	1.1%	37
2025 Q2	$2.89M	Sell	308,298 -28,900	-9%	-$318K	2.15%	19
2025 Q1	$4.14M	Buy	337,198 +18,298	+6%	+$258K	3.68%	6
2024 Q4	$4.22M	Buy	+318,900	New	+$5.46M	3.17%	8

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Exome Asset Management's SNDX Position: Q4 2025 in Review

Exome Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 117,783 shares — an estimated $1.81M sold.

Exome Asset Management first reported a position in SNDX in Q4 2024 and held it in 4 quarters. The position peaked at $4.22M in Q4 2024. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Exome Asset Management reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Exome Asset Management sold 117,783 Syndax Pharmaceuticals shares in Q4 2025, an estimated $1.81M.
Exome Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Exome Asset Management's Syndax Pharmaceuticals position peaked at $4.22M in Q4 2024.
229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.